A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone
SA Rosenberg, MT Lotze, LM Muul, AE Chang, FP Avis, S Leitman, WM Linehan, CN Robertson, RE Lee, JT Rubin, and et al.
We studied the effects of adoptive immunotherapy with lymphokine-activated killer (LAK) cells plus interleukin-2 or therapy with high-dose interleukin-2 alone in 157 patients with metastatic cancer for whom standard therapy had proved ineffective or no standard effective treatment was available. One hundred eight patients were treated with 127 courses of LAK cells plus interleukin-2, and 49 patients were treated with 53 courses of high-dose interleukin-2 alone. Of 106 evaluable patients receiving LAK cells plus interleukin-2, 8 had complete responses, 15 had partial responses, and 10 had minor responses. The median duration of response was 10 months among those with complete responses and 6 months among those with partial responses; the patient with the longest complete response was still in remission 22 months after treatment. Of 46 evaluable patients treated with high-dose interleukin-2 alone, 1 had a complete response (remission greater than 4 months), 5 had partial responses (2, greater than 3, greater than 5, 7, and greater than 11 months), and 1 had a minor response. Seven of the total of nine complete responses still remain in remission. Hypotension, weight gain, oliguria, and elevation of bilirubin and creatinine levels were common, but these side effects resolved promptly after interleukin-2 administration was stopped. There have been four treatment-related deaths among these 157 patients. This immunotherapeutic approach can result in marked tumor regression in some patients for whom no other effective therapy is available at present. Determining its ultimate role in cancer therapy awaits further attempts to increase the therapeutic efficacy of treatment and decrease its toxicity and complexity.
This article has been cited by other articles:
Hipp, M. M., Hilf, N., Walter, S., Werth, D., Brauer, K. M., Radsak, M. P., Weinschenk, T., Singh-Jasuja, H., Brossart, P.
(2008). Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood
111: 5610-5620
[Abstract][Full Text]
Chapman, P. B.
(2008). Combining a Peptide Vaccine With High-Dose Interleukin-2. JCO
26: 2250-2251
[Full Text]
Whitson, B. A., Groth, S. S., Andrade, R. S., Garrett, L., Dudek, A. Z., Jessurun, J., Maddaus, M. A.
(2008). Extension of survival by resection of asynchronous renal cell carcinoma metastases to mediastinal lymph nodes.. J. Thorac. Cardiovasc. Surg.
135: 1022-1028
[Abstract][Full Text]
Schlom, J., Gulley, J. L., Arlen, P. M.
(2008). Paradigm Shifts in Cancer Vaccine Therapy. Exp. Biol. Med.
233: 522-534
[Abstract][Full Text]
Schlom, J., Arlen, P. M., Gulley, J. L.
(2007). Cancer Vaccines: Moving Beyond Current Paradigms. Clin. Cancer Res.
13: 3776-3782
[Abstract][Full Text]
Patel, P. H., Chadalavada, R. S.V., Chaganti, R.S.K., Motzer, R. J.
(2006). Targeting von Hippel-Lindau Pathway in Renal Cell Carcinoma. Clin. Cancer Res.
12: 7215-7220
[Abstract][Full Text]
Parton, M., Gore, M., Eisen, T.
(2006). Role of Cytokine Therapy in 2006 and Beyond for Metastatic Renal Cell Cancer. JCO
24: 5584-5592
[Abstract][Full Text]
Duval, L., Schmidt, H., Kaltoft, K., Fode, K., Jensen, J. J., Sorensen, S. M., Nishimura, M. I., von der Maase, H.
(2006). Adoptive Transfer of Allogeneic Cytotoxic T Lymphocytes Equipped with a HLA-A2 Restricted MART-1 T-Cell Receptor: A Phase I Trial in Metastatic Melanoma. Clin. Cancer Res.
12: 1229-1236
[Abstract][Full Text]
Schwinger, W., Klass, V., Benesch, M., Lackner, H., Dornbusch, H. J., Sovinz, P., Moser, A., Schwantzer, G., Urban, C.
(2005). Feasibility of high-dose interleukin-2 in heavily pretreated pediatric cancer patients. Ann Oncol
16: 1199-1206
[Abstract][Full Text]
Nguyen, S., Dhedin, N., Vernant, J.-P., Kuentz, M., Jijakli, A. A., Rouas-Freiss, N., Carosella, E. D., Boudifa, A., Debre, P., Vieillard, V.
(2005). NK-cell reconstitution after haploidentical hematopoietic stem-cell transplantations: immaturity of NK cells and inhibitory effect of NKG2A override GvL effect. Blood
105: 4135-4142
[Abstract][Full Text]
Miller, J. S., Soignier, Y., Panoskaltsis-Mortari, A., McNearney, S. A., Yun, G. H., Fautsch, S. K., McKenna, D., Le, C., Defor, T. E., Burns, L. J., Orchard, P. J., Blazar, B. R., Wagner, J. E., Slungaard, A., Weisdorf, D. J., Okazaki, I. J., McGlave, P. B.
(2005). Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood
105: 3051-3057
[Abstract][Full Text]
Liu, D., O'Day, S. J., Yang, D., Boasberg, P., Milford, R., Kristedja, T., Groshen, S., Weber, J.
(2005). Impact of Gene Polymorphisms on Clinical Outcome for Stage IV Melanoma Patients Treated with Biochemotherapy: An Exploratory Study. Clin. Cancer Res.
11: 1237-1246
[Abstract][Full Text]
Shibata, H., Yoshioka, Y., Ikemizu, S., Kobayashi, K., Yamamoto, Y., Mukai, Y., Okamoto, T., Taniai, M., Kawamura, M., Abe, Y., Nakagawa, S., Hayakawa, T., Nagata, S., Yamagata, Y., Mayumi, T., Kamada, H., Tsutsumi, Y.
(2004). Functionalization of Tumor Necrosis Factor-{alpha} Using Phage Display Technique and PEGylation Improves Its Antitumor Therapeutic Window. Clin. Cancer Res.
10: 8293-8300
[Abstract][Full Text]
Shibuya, T. Y., Kim, S., Nguyen, K., Do, J., McLaren, C. E., Li, K.-T., Chen, W.-P., Parikh, P., Wadhwa, A., Zi, X., Chen, V. Y., Wong, H.-S., Armstrong, W. B., Yoo, G. H.
(2004). Bioactive Suture: A Novel Immunotherapy for Head and Neck Cancer. Clin. Cancer Res.
10: 7088-7099
[Abstract][Full Text]
Assier, E., Jullien, V., Lefort, J., Moreau, J.-L., Di Santo, J. P., Vargaftig, B. B., Lapa e Silva, J. R., Theze, J.
(2004). NK Cells and Polymorphonuclear Neutrophils Are Both Critical for IL-2-Induced Pulmonary Vascular Leak Syndrome. J. Immunol.
172: 7661-7668
[Abstract][Full Text]
Negrier, S.
(2004). Better Survival With Interleukin-2-Based Regimens? Possibly Only in Highly Selected Patients. JCO
22: 1174-1176
[Full Text]
Atzpodien, J., Kirchner, H., Jonas, U., Bergmann, L., Schott, H., Heynemann, H., Fornara, P., Loening, S.A., Roigas, J., Muller, S.C., Bodenstein, H., Pomer, S., Metzner, B., Rebmann, U., Oberneder, R., Siebels, M., Wandert, T., Puchberger, T., Reitz, M.
(2004). Interleukin-2- and Interferon Alfa-2a-Based Immunochemotherapy in Advanced Renal Cell Carcinoma: A Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). JCO
22: 1188-1194
[Abstract][Full Text]
Tourani, J.-M., Pfister, C., Tubiana, N., Ouldkaci, M., Prevot, G., Lucas, V., Oudard, S., Malet, M., Cottu, P., Ferrero, J.-M., Mayeur, D., Rixe, O., Sun, X.-S., Bernard, O., Andre, T., Tournigand, C., Muracciole, X., Guilhot, J.
(2003). Subcutaneous Interleukin-2 and Interferon Alfa Administration in Patients With Metastatic Renal Cell Carcinoma: Final Results of SCAPP III, a Large, Multicenter, Phase II, Nonrandomized Study With Sequential Analysis Design--The Subcutaneous Administration Propeukin Program Cooperative Group. JCO
21: 3987-3994
[Abstract][Full Text]
Kimura, Y., Mizuno, H., Satake, K., Tahara, H., Tsukuda, M.
(2003). Effects of Combined Therapy With Interleukin 2 and Interleukin 12 Gene-Transfected Tumor Vaccine for Head and Neck Carcinoma. Arch Otolaryngol Head Neck Surg
129: 1181-1185
[Abstract][Full Text]
Lara, P. N. Jr., Quinn, D. I., Margolin, K., Meyers, F. J., Longmate, J., Frankel, P., Mack, P. C., Turrell, C., Valk, P., Rao, J., Buckley, P., Wun, T., Gosselin, R., Galvin, I., Gumerlock, P. H., Lenz, H. J., Doroshow, J. H., Gandara, D. R.
(2003). SU5416 Plus Interferon {alpha} in Advanced Renal Cell Carcinoma: A Phase II California Cancer Consortium Study with Biological and Imaging Correlates of Angiogenesis Inhibition. Clin. Cancer Res.
9: 4772-4781
[Abstract][Full Text]
Thakur, M. L., Coss, R., Howell, R., Vassileva-Belnikolovska, D., Liu, J., Rao, S. P., Spana, G., Wachsberger, P., Leeper, D. L.
(2003). Role of Lipid-Soluble Complexes in Targeted Tumor Therapy. JNM
44: 1293-1300
[Abstract][Full Text]
Hu, P., Mizokami, M., Ruoff, G., Khawli, L. A., Epstein, A. L.
(2003). Generation of low-toxicity interleukin-2 fusion proteins devoid of vasopermeability activity. Blood
101: 4853-4861
[Abstract][Full Text]
Li, Q., Carr, A., Ito, F., Teitz-Tennenbaum, S., Chang, A. E.
(2003). Polarization Effects of 4-1BB during CD28 Costimulation in Generating Tumor-reactive T Cells for Cancer Immunotherapy. Cancer Res.
63: 2546-2552
[Abstract][Full Text]
Messing, E. M., Manola, J., Wilding, G., Propert, K., Fleischmann, J., Crawford, E. D., Pontes, J. E., Hahn, R., Trump, D.
(2003). Phase III Study of Interferon Alfa-NL as Adjuvant Treatment for Resectable Renal Cell Carcinoma: An Eastern Cooperative Oncology Group/Intergroup Trial. JCO
21: 1214-1222
[Abstract][Full Text]
Stift, A., Friedl, J., Dubsky, P., Bachleitner-Hofmann, T., Schueller, G., Zontsich, T., Benkoe, T., Radelbauer, K., Brostjan, C., Jakesz, R., Gnant, M.
(2003). Dendritic Cell-Based Vaccination in Solid Cancer. JCO
21: 135-142
[Abstract][Full Text]
Storb, R. F., Lucarelli, G., McSweeney, P. A., Childs, R. W.
(2003). Hematopoietic Cell Transplantation for Benign Hematological Disorders and Solid Tumors. ASH Education Book
2003: 372-397
[Abstract][Full Text]
Escudier, B., Lassau, N., Couanet, D., Angevin, E., Mesrati, F., Leborgne, S., Garofano, A., Leboulaire, C., Dupouy, N., Laplanche, A.
(2002). Phase II trial of thalidomide in renal-cell carcinoma. Ann Oncol
13: 1029-1035
[Abstract][Full Text]
Hayashi, M., Tomita, M., Yoshizato, K.
(2002). Interleukin-2-collagen chimeric protein which liberates interleukin-2 upon collagenolysis. Protein Eng Des Sel
15: 429-436
[Abstract][Full Text]
Cheng, L. E., Ohlen, C., Nelson, B. H., Greenberg, P. D.
(2002). Enhanced signaling through the IL-2 receptor in CD8+ T cells regulated by antigen recognition results in preferential proliferation and expansion of responding CD8+ T cells rather than promotion of cell death. Proc. Natl. Acad. Sci. USA
10.1073/pnas.052676899v1
[Abstract][Full Text]
Leong, S. P. L., Peng, M., Zhou, Y.-M., Vaquerano, J. E., Chang, J. W. C.
(2002). Cytokine Profiles of Sentinel Lymph Nodes Draining the Primary Melanoma. Ann. Surg. Oncol.
9: 82-87
[Abstract][Full Text]
Buzaid, A. C., Atkins, M.
(2001). Practical Guidelines for the Management of Biochemotherapy-related Toxicity in Melanoma. Clin. Cancer Res.
7: 2611-2619
[Abstract][Full Text]
De Paoli, P.
(2001). Immunological Effects of Interleukin-2 Therapy in Human Immunodeficiency Virus-Positive Subjects. CVI
8: 671-677
[Full Text]
Nakano, O., Sato, M., Naito, Y., Suzuki, K., Orikasa, S., Aizawa, M., Suzuki, Y., Shintaku, I., Nagura, H., Ohtani, H.
(2001). Proliferative Activity of Intratumoral CD8+ T-Lymphocytes As a Prognostic Factor in Human Renal Cell Carcinoma: Clinicopathologic Demonstration of Antitumor Immunity. Cancer Res.
61: 5132-5136
[Abstract][Full Text]
Sharma, S., White, D., Imondi, A. R., Placke, M. E., Vail, D. M., Kris, M. G.
(2001). Development of Inhalational Agents for Oncologic Use. JCO
19: 1839-1847
[Abstract][Full Text]
Negrier, S., Caty, A., Lesimple, T., Douillard, J.-Y., Escudier, B., Rossi, J.-F., Viens, P., Gomez, F.
(2000). Treatment of Patients With Metastatic Renal Carcinoma With a Combination of Subcutaneous Interleukin-2 and Interferon Alfa With or Without Fluorouracil. JCO
18: 4009-4015
[Abstract][Full Text]
To, W. C., Wood, B. G., Krauss, J. C., Strome, M., Esclamado, R. M., Lavertu, P., Dasko, D., Kim, J. A., Plautz, G. E., Leff, B. E., Smith, V., Sandstrom-Wakeling, K., Shu, S.
(2000). Systemic Adoptive T-Cell Immunotherapy in Recurrent and Metastatic Carcinoma of the Head and Neck: A Phase 1 Study. Arch Otolaryngol Head Neck Surg
126: 1225-1231
[Abstract][Full Text]
Shallal, S., Kornbluth, J.
(2000). CD9 expression enhances the susceptibility of myeloma cell lines to cell-mediated cytolysis. Blood
96: 224-233
[Abstract][Full Text]
Kawamura, A. Jr, Sekine, T., Sekiguchi, M., Yanoma, S., Kaneko, A., Haneda, T., Moriya, Y., Hayasaka, K.-i., Kakizoe, T.
(2000). Six-year Disease-free Survival of a Patient with Metastatic Eyelid Squamous Cell Carcinoma and Colon Adenocarcinoma after Repeated Postoperative Adoptive Immunotherapy. Jpn J Clin Oncol
30: 267-271
[Abstract][Full Text]
Capuron, L., Ravaud, A., Dantzer, R.
(2000). Early Depressive Symptoms in Cancer Patients Receiving Interleukin 2 and/or Interferon Alfa-2b Therapy. JCO
18: 2143-2151
[Abstract][Full Text]
Visonneau, S., Cesano, A., Porter, D. L., Luger, S. L., Schuchter, L., Kamoun, M., Torosian, M. H., Duffy, K., Sickles, C., Stadtmauer, E. A., Santoli, D.
(2000). Phase I Trial of TALL-104 Cells in Patients with Refractory Metastatic Breast Cancer. Clin. Cancer Res.
6: 1744-1754
[Abstract][Full Text]
Yoneda, O., Imai, T., Goda, S., Inoue, H., Yamauchi, A., Okazaki, T., Imai, H., Yoshie, O., Bloom, E. T., Domae, N., Umehara, H.
(2000). Fractalkine-Mediated Endothelial Cell Injury by NK Cells. J. Immunol.
164: 4055-4062
[Abstract][Full Text]
de Gast, G. C., Klümpen, H.-J., Vyth-Dreese, F. A., Kersten, M.-J., Verra, N. C. V., Sein, J., Batchelor, D., Nooijen, W. J., Schornagel, J. H.
(2000). Phase I Trial of Combined Immunotherapy with Subcutaneous Granulocyte Macrophage Colony-stimulating Factor, Low-Dose Interleukin 2, and Interferon {{alpha}} in Progressive Metastatic Melanoma and Renal Cell Carcinoma. Clin. Cancer Res.
6: 1267-1272
[Abstract][Full Text]
Heinzer, H., Mir, T. S., Huland, E., Huland, H.
(1999). Subjective and Objective Prospective, Long-Term Analysis of Quality of Life During Inhaled Interleukin-2 Immunotherapy. JCO
17: 3612-3620
[Abstract][Full Text]
Kozlowski, M., Schorey, J., Portis, T., Grigoriev, V., Kornbluth, J.
(1999). NK Lytic-Associated Molecule: A Novel Gene Selectively Expressed in Cells with Cytolytic Function. J. Immunol.
163: 1775-1785
[Abstract][Full Text]
Motzer, R. J., Mazumdar, M., Bacik, J., Berg, W., Amsterdam, A., Ferrara, J.
(1999). Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma. JCO
17: 2530-2530
[Abstract][Full Text]
Escudier, B., Chevreau, C., Lasset, C., Douillard, J. Y., Ravaud, A., Fabbro, M., Caty, A., Rossi, J. F., Viens, P., Bergerat, J. P., Savary, J., Negrier, S.
(1999). Cytokines in Metastatic Renal Cell Carcinoma: Is It Useful to Switch to Interleukin-2 or Interferon After Failure of a First Treatment?. JCO
17: 2039-2039
[Abstract][Full Text]
Atkins, M. B., Lotze, M. T., Dutcher, J. P., Fisher, R. I., Weiss, G., Margolin, K., Abrams, J., Sznol, M., Parkinson, D., Hawkins, M., Paradise, C., Kunkel, L., Rosenberg, S. A.
(1999). High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993. JCO
17: 2105-2105
[Abstract][Full Text]
Tsunoda, S., Ishikawa, T., Yamamoto, Y., Kamada, H., Koizumi, K., Matsui, J., Tsutsumi, Y., Hirano, T., Mayumi, T.
(1999). Enhanced Antitumor Potency of Polyethylene Glycolylated Tumor Necrosis Factor-alpha : A Novel Polymer-Conjugation Technique with a Reversible Amino-Protective Reagent. J. Pharmacol. Exp. Ther.
290: 368-372
[Abstract][Full Text]
Visonneau, S., Cesano, A., Jeglum, K. A., Santoli, D.
(1999). Adjuvant Treatment of Canine Osteosarcoma with the Human Cytotoxic T-Cell Line TALL-104. Clin. Cancer Res.
5: 1868-1875
[Abstract][Full Text]
Horiguchi, S., Petersson, M., Nakazawa, T., Kanda, M., Zea, A. H., Ochoa, A. C., Kiessling, R.
(1999). Primary Chemically Induced Tumors Induce Profound Immunosuppression Concomitant with Apoptosis and Alterations in Signal Transduction in T Cells and NK Cells. Cancer Res.
59: 2950-2956
[Abstract][Full Text]
Li, D., Jiang, W., Bishop, J. S., Ralston, R., O'Malley, B. W. Jr.
(1999). Combination Surgery and Nonviral Interleukin 2 Gene Therapy for Head and Neck Cancer. Clin. Cancer Res.
5: 1551-1556
[Abstract][Full Text]
Sampath, P., Hanes, J., DiMeco, F., Tyler, B. M., Brat, D., Pardoll, D. M., Brem, H.
(1999). Paracrine Immunotherapy with Interleukin-2 and Local Chemotherapy Is Synergistic in the Treatment of Experimental Brain Tumors. Cancer Res.
59: 2107-2114
[Abstract][Full Text]
Baluna, R., Rizo, J., Gordon, B. E., Ghetie, V., Vitetta, E. S.
(1999). Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. Proc. Natl. Acad. Sci. USA
96: 3957-3962
[Abstract][Full Text]
Franzke, A., Peest, D., Probst-Kepper, M., Buer, J., Kirchner, G. I., Brabant, G., Kirchner, H., Ganser, A., Atzpodien, J.
(1999). Autoimmunity Resulting From Cytokine Treatment Predicts Long-Term Survival in Patients With Metastatic Renal Cell Cancer. JCO
17: 529-529
[Abstract][Full Text]
Strau{beta}, G., Guckel, B., Wallwiener, D., Moldenhauer, G.
(1999). Without Prior Stimulation, Tumor-associated Lymphocytes from Malignant Effusions Lyse Autologous Tumor Cells in the Presence of Bispecific Antibody HEA125xOKT3. Clin. Cancer Res.
5: 171-180
[Abstract][Full Text]
Gleave, M. E., Elhilali, M., Fradet, Y., Davis, I., Venner, P., Saad, F., Klotz, L. H., Moore, M. J., Paton, V., Bajamonde, A., Bell, D., Ernst, S., Ramsey, E., Chin, J., Morales, A., Martins, H., Sanders, C., The Canadian Urologic Oncology Group,
(1998). Interferon Gamma-1b Compared with Placebo in Metastatic Renal-Cell Carcinoma. NEJM
338: 1265-1271
[Abstract][Full Text]
Negrier, S., Escudier, B., Lasset, C., Douillard, J.-Y., Savary, J., Chevreau, C., Ravaud, A., Mercatello, A., Peny, J., Mousseau, M., Philip, T., Tursz, T., The Groupe Francais d'Immunotherapie,
(1998). Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma. NEJM
338: 1272-1278
[Abstract][Full Text]
Nguyen, Q. H., Roberts, R. L., Ank, B. J., Lin, S.-J., Lau, C. K., Stiehm, E. R.
(1998). Enhancement of Antibody-Dependent Cellular Cytotoxicity of Neonatal Cells by Interleukin-2 (IL-2) and IL-12. CVI
5: 98-104
[Abstract][Full Text]
Korholz, D., Banning, U., Bonig, H., Grewe, M., Schneider, M., Mauz-Korholz, C., Klein-Vehne, A., Krutmann, J., Burdach, S.
(1997). The Role of Interleukin-10 (IL-10) in IL-15-Mediated T-Cell Responses. Blood
90: 4513-4521
[Abstract][Full Text]
Porgador, A., Mandelboim, O., Restifo, N. P., Strominger, J. L.
(1997). Natural killer cell lines kill autologous beta 2-microglobulin-deficient melanoma cells: Implications for cancer immunotherapy. Proc. Natl. Acad. Sci. USA
94: 13140-13145
[Abstract][Full Text]
Lieberman, J., Skolnik, P. R., Parkerson III, G. R., Fabry, J. A., Landry, B., Bethel, J., Kagan, J., the DATRI 006 Study Team,
(1997). Safety of Autologous, Ex Vivo-Expanded Human Immunodeficiency Virus (HIV)-Specific Cytotoxic T-Lymphocyte Infusion in HIV-Infected Patients. Blood
90: 2196-2206
[Abstract][Full Text]
O’Malley, B. W. Jr., Sewell, D. A., Li, D., Kosai, K.-i., Chen, S.-H., Woo, S. L.C., Duan, L.
(1997). The Role of Interleukin-2 in Combination Adenovirus Gene Therapy for Head and Neck Cancer. Mol. Endocrinol.
11: 667-673
[Abstract][Full Text]
Kwong, L. K., Ridinger, D. N., Bandhauer, M., Ward, J. H., Samlowski, W. E., Iverius, P.-H., Pritchard, H., Wilson, D. E.
(1997). Acute Dyslipoproteinemia Induced by Interleukin-2: Lecithin:Cholesteryl Acyltransferase, Lipoprotein Lipase, and Hepatic Lipase Deficiencies. J. Clin. Endocrinol. Metab.
82: 1572-1581
[Abstract][Full Text]
Motzer, R. J., Bander, N. H., Nanus, D. M.
(1996). Renal-Cell Carcinoma. NEJM
335: 865-875
[Full Text]
Legrès, L. G., Pochon, F., Barray, M., Gay, F., Chouaib, S., Delain, E.
(1995). Evidence for the Binding of a Biologically Active Interleukin-2 to Human [IMAGE][IMAGE]-Macroglobulin. J. Biol. Chem.
270: 8381-8384
[Abstract][Full Text]
Ceballos, P. I., Ruiz-Maldonado, R., Mihm, M. C.
(1995). Melanoma in Children. NEJM
332: 656-662
[Full Text]
Lindley, C. M., Gordon, T. R.
(1991). Application of Biotechnology Products in Oncology. Journal of Pharmacy Practice
4: 117-130
Hatakeyama, M, Tsudo, M, Minamoto, S, Kono, T, Doi, T, Miyata, T, Miyasaka, M, Taniguchi, T
(1989). Interleukin-2 receptor beta chain gene: generation of three receptor forms by cloned human alpha and beta chain cDNA's. Science
244: 551-556
[Abstract]
Hanker, J., Giammara, B.
(1988). Biomaterials and biomedical devices. Science
242: 885-892
[Abstract]
Smith, K.
(1988). Interleukin-2: inception, impact, and implications. Science
240: 1169-1176
[Abstract]
Barnes, D.
(1987). Biologics gain influence in expanding NCI program. Science
237: 848-850
Cheng, L. E., Ohlen, C., Nelson, B. H., Greenberg, P. D.
(2002). Enhanced signaling through the IL-2 receptor in CD8+ T cells regulated by antigen recognition results in preferential proliferation and expansion of responding CD8+ T cells rather than promotion of cell death. Proc. Natl. Acad. Sci. USA
99: 3001-3006
[Abstract][Full Text]
